Tmunity Therapeutics Raises $75 Million

Want to share this story?

A health tech startup which aims to introduce the next generation of T-cell immunotherapy, announced it has closed on its latest funding round.

Tmunity Therapeutics raised $75 million in Series B financing, led by Andreessen Horowitz. Other participants are a16z’s Cultural Leadership Fund    (a part of Andreessen Horrowitz), BrightEdge, Be The Match BioTherapies (American Cancer Society’s philanthropic impact fund), Westlake Village BioPartners, Gilead Sciences, and the The University of Pennsylvania.

The total funding for Tmunity including this latest one is $231 million.

Tmunity develops and uses new technologies to find smarter cells to fight cancer and other diseases. The startup plans to use the new funding to continue funding ongoing and planed research, clinical development of product candidates, continued build out of its proprietary, vertically-integrated viral vector and cell therapy product manufacturing, working capital and other purposes.

Jorge Conde, General Partner at Andreessen Horowitz, has been named to the company’s board of directors.